Oncolytics Biotech (TSE:ONC) Shares Pass Above 200 Day Moving Average – What’s Next?

Shares of Oncolytics Biotech Inc. (TSE:ONC) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$13.50 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares traded.

Oncolytics Biotech Price Performance

The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The firm has a fifty day moving average of C$14.90 and a two-hundred day moving average of C$13.50. The stock has a market capitalization of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80.

Insider Activity

In other Oncolytics Biotech news, Director Patricia Andrews acquired 35,400 shares of the company’s stock in a transaction dated Thursday, February 12th. The shares were purchased at an average cost of C$1.18 per share, for a total transaction of C$41,772.00. Following the completion of the purchase, the director owned 78,128 shares in the company, valued at approximately C$92,191.04. This trade represents a 82.85% increase in their ownership of the stock. Also, insider Jared Ryan Kelly acquired 29,500 shares of Oncolytics Biotech stock in a transaction that occurred on Thursday, February 12th. The stock was acquired at an average cost of C$1.16 per share, with a total value of C$34,220.00. Following the purchase, the insider directly owned 109,000 shares of the company’s stock, valued at C$126,440. This represents a 37.11% increase in their ownership of the stock. In the last quarter, insiders purchased 289,232 shares of company stock valued at $335,760. 3.82% of the stock is currently owned by corporate insiders.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.